Affimed NV
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- -
- Employees
- 78
- Market Cap
- $63.9M
- Introduction
Affimed NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of cancer immunotherapies. The company’s proprietary ROCK platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. It operates through the Germany and USA geographical segments. The company was founded in 2000 and is headquartered in Mannheim, Germany.
Combination Therapy in Non-Small Cell Lung Cancer (NSCLC)
Affimed announced positive clinical data for AFM24/atezolizumab combination therapy in NSCLC, showing efficacy in EGFRwt and EGFRmut patients with good tolerability. Higher AFM24 exposure linked to better response rates, PFS, and OS. Future development will use a 720 mg weekly dose, tested successfully in phase 1, indicating a manageable safety profile.
Affimed Reports Positive Clinical Update on AFM24/Atezolizumab Combination Therapy in Non-Small Cell Lung Cancer (NSCLC)
AFM24 combined with atezolizumab shows promising results in heavily pretreated NSCLC patients, with ORR of 21% in EGFRwt and 24% in EGFRmut patients, DCR of 76% and 71% respectively, and median PFS of 5.6 months. Higher AFM24 exposure correlates with better outcomes, leading to a planned 720 mg weekly dose in future trials.
© Copyright 2025. All Rights Reserved by MedPath